Indian pharmaceutical major Wockhardt has announced that its novel antibiotic, Zaynich (cefepime and zidebactam), has secured approval from the US Food and Drug Administration (FDA). This significant clearance targets adults suffering from complicated urinary tract infections (cUTI) and acute kidney infections, offering a new weapon in the global battle against antimicrobial resistance.
The approval is particularly noteworthy as Zaynich represents the first new chemical entity (NCE) — a completely new drug — to be fully developed and commercialized by an Indian pharmaceutical company that has successfully navigated the stringent US FDA approval process. This achievement follows a recent marketing authorization granted by India's drug regulator.
A Breakthrough Against Drug Resistance
Zaynich operates through a unique dual-action mechanism designed to overcome various forms of bacterial resistance, a critical feature given the escalating crisis of drug-resistant infections worldwide. The therapy aims to address some of the most challenging bacterial infections where existing treatment options are often limited or ineffective.
Dr. Habil F. Khorakiwala, Founder and Chairman of Wockhardt Group, emphasized the broader impact of this approval.
"This approval is a significant realization of our mission to provide patients with novel antibiotics that help to address one of the most urgent global health threats—antimicrobial resistance," said Dr. Khorakiwala. "Furthermore, ZAYNICH is the first New Chemical Entity fully developed and commercialized by an Indian pharmaceutical company to receive an FDA approval, representing a historic milestone not only for Wockhardt, but for the Indian pharmaceutical industry."
Positive Clinical Trial Results
The FDA's decision was based on robust data from the global Phase 3 ENHANCE-1 study. This trial involved 530 hospitalized adult patients across 64 hospitals and research centers spanning the US, Europe, Latin America, China, and India. The study compared Zaynich's efficacy against meropenem, a widely used antibiotic, in treating cUTI and acute kidney infections.
Wockhardt reported compelling results, with 89% of patients treated with Zaynich demonstrating both clinical recovery and elimination of the infection. This significantly outperformed meropenem, which showed a 68.4% success rate, giving Zaynich a treatment advantage of 20.6 percentage points.
"The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens," stated Dennis Deruelle, Chief Medical Officer at Wockhardt. "The FDA approval of ZAYNICH is a monumental step forward in validating a new option for these underserved populations."
The urgency of new antibiotics is underscored by alarming statistics: over 2.8 million antimicrobial-resistant infections occur annually in the US, leading to more than 35,000 deaths.
Keith Kaye, Professor of Medicine and Division Chief for Infectious Diseases at Rutgers Robert Wood Johnson Medical School, highlighted the critical need. "Multidrug-resistant bacterial infections are a substantial burden for patients and the healthcare system, as patients with these infections typically require longer, more intensive care, and are at increased risk of life-threatening complications. There is an ongoing need for new antibiotics to combat these drug-resistant pathogens, and we are pleased that this approval means patients will soon have an exciting unique option that is urgently needed in the US and worldwide."
Expedited Review and Future Prospects
Zaynich had previously received several fast-track designations from the US FDA, including Priority Review, Fast Track, and Qualified Infectious Disease Product (QIDP) status. These programs are designed to accelerate the development and review of medicines addressing significant unmet medical needs, particularly for urgently required antibiotics.
Beyond the US, Wockhardt has also made Zaynich available through expanded access programs in multiple countries for patients with limited treatment options. The company has further submitted a marketing authorization application for the drug in Europe, which is currently under regulatory review. This approval strengthens Wockhardt's antibiotic pipeline, which includes six programs at various stages of development, all of which have received QIDP designation from the US FDA.